Lowest Price Guaranteed From USD 4,799
Published
November 2022
Pages
270
View Count
14423
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
The space of bioavailability enhancement technologies and services, driven by the increase in number of BCS II and BCS IV molecules in early phases of development, is likely reach USD 10 billion by 2035, growing at a CAGR of ~11%. Bioavailability is known to form an integral part of the drug pharmacokinetics. As a result, over the last couple of years, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. Further, a study conducted on terminated drug development projects revealed that majority of the candidates fail in early phases. The study further highlighted that the aforementioned drug failures can primarily be attributed to the problems associated with pharmacokinetic profiles, ADME (distribution, metabolism, absorption and excretion) properties and toxicity-related concerns. At present, more than 40% of the marketed drugs are believed to possess low bioavailability, while around 90% of all New Chemical Entities (NCEs), which are being evaluated in pre-clinical and clinical stages of development, exhibit solubility / permeability related issues.Consequently, recent years have seen a rise in drug developers evaluating various re-formulation strategies to improve the bioavailability of existing drugs / drug candidates. In fact, an increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability.
In this context, it is also important to mention that a significant number of players engaged in the development of therapeutic interventions currently prefer to outsource their bioavailability enhancement operations to contract service providers. This trend can be attributed to the fact that service providers usually have specialized facilities and equipment, along with established processes, which can help drug developers to accomplish the desired goals in shorter timelines. In order to cater to the requirement for such services, a number of bioavailability enhancement focused service providers for API have been established in the past few years, across various regions of the globe. At present, the bioavailability enhancement service providers are actively trying to consolidate their presence in this field by entering into strategic alliances, to meet the indubitably rising demand for effective therapeutics. For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market. In fact, since 2017, close to 6,000 research articles, evaluating various bioavailability enhancement techniques have been published across several reputed journals. In addition, close to 10,000 patents have been filed, till 2022, providing a significant scientific push for the development of novel approaches. Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is expected to grow at a steady pace in the foreseen future.
Several recent developments have taken place in the field of bioavailability enhancement. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Bioavailability Enhancement Technologies and Services Market (2nd Edition) by Drug Class (New Drug Approvals and Generics), BCS Classification (BCS II Drugs and BCS IV Drugs), Bioavailability Enhancement Approach (Solid Dispersion, Size Reduction, Lipid-based, and Other Approaches), Dosage Form (Liquids, Solids, Semi-Solids, and Fine Particles) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the bioavailability enhancement technologies and services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing bioavailability enhancement technologies and services. The table below highlights various market segmentations done in the report.
Report Attribute | Details | |
Forecast Period |
2022 – 2035 |
|
Drug Class |
New Drug Approvals, Generics | |
BCS Classification |
BCS II drugs, BCS IV drugs | |
Bioavailability Enhancement Approach |
Solid dispersion, size reduction, lipid-based | |
Dosage Form |
Liquids, solids, semi-solids, fine particles / powders | |
Key Geographical Regions | North America, Europe, Asia-Pacific, MENA, Latin America and Rest of the World |
Amongst other elements, the report features:
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bioavailability Enhancement Technologies
3.3. Assessment of Drug Bioavailability
3.3.1. Key Considerations for Bioavailability and Assessment Studies
3.3.1.1. Absolute Bioavailability
3.3.1.2. Relative Bioavailability
3.3.1.3. Single and Multiple Dose Studies
3.3.2. Studies in Healthy Subjects and Patients
3.3.2.1. Different Bioavailability Assessment methods
3.4. Need for Bioavailability Enhancement
3.5. Factors Affecting Bioavailability
3.5.1. Drug Related Factors
3.5.2. Patient Physiology Related Factors
3.6. Bioavailability Enhancement Technologies
3.6.1. Physical Technologies for Bioavailability Enhancement
3.6.1.1. Solid Dispersion
3.6.1.1.1. Classification of Solid Dispersion Approaches
3.6.1.1.2. Methodologies for Solid Dispersion Approaches
3.6.1.1.2.1. Hot Melt Extrusion
3.6.1.1.2.2. Solvent Evaporation
3.6.1.1.2.3. Spray-Dried Dispersion
3.6.1.1.2.4. Other Techniques Used for Solid Dispersion
3.6.1.2. Nanosuspension Technology
3.6.1.2.1. Top-Down Approach
3.6.1.2.2. Bottom-Up Approach
3.6.2. Chemical Technologies for Bioavailability Enhancement
3.6.2.1. Lipid-Based Formulations
3.6.2.2. Non-Metal-Based Drug Delivery Systems
3.6.2.3. Polymer-Based Drug Delivery Systems
3.6.3. Biological Technologies for Bioavailability Enhancement
3.7. Concluding remarks
4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Bioavailability Enhancement Principle
4.2.5. Analysis by Bioavailability Enhancement Approach
4.2.5.1. Analysis by Solid Dispersion Approaches
4.2.5.2. Analysis by Size Reduction Approaches
4.2.5.3. Analysis by Lipid-Based Approaches
4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
4.2.6. Analysis by Dosage Form
4.2.7. Analysis by Route of Administration
5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Players: Analysis by Number of Technologies
5.3. Bioavailability Enhancement Technologies: Market Landscape
5.3.1. Analysis by Bioavailability Enhancement Principle
5.3.2. Analysis by Bioavailability Enhancement Approach
5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability EnhancementApproach
5.3.4. Analysis by Type of Molecule
5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
5.3.6. Analysis by Dosage Form
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Availability for License
5.3.9. Analysis by Intellectual Property Rights
6. KEY INSIGHTS
6.1. Chapter Overview
6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Adare Pharma Solutions
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. Ascendia Pharmaceuticals
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. Catalent
7.4.1. Company Overview
7.4.2. Financial Overview
7.4.3. Recent Developments and Future Outlook
7.5. Lonza
7.5.1. Company Overview
7.5.2. Financial Overview
7.5.3. Recent Developments and Future Outlook
7.6. Lubrizol Life Science Health
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. Pace Life Sciences
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. Quotient Sciences
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook
7.10. WuXi STA (A Subsidiary of WuXi AppTec)
7.10.1. Company Overview
7.10.2. Financial Overview
7.10.3. Recent Developments and Future Outlook
8. COMPANY BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
8.3.1. Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
8.3.3. Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
8.3.4. Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
8.3.6. Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post -2000 (Peer Group VIII)
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Type of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.4. Analysis by Geography
9.4.1. Analysis by Region
9.4.2. Analysis by Country
9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bioavailability Enhancement: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Bioavailability Enhancement Approach
10.3.4. Analysis by Year of Publication and Bioavailability Enhancement Approach
10.3.5. Most Popular Journals: Analysis by Number of Publications
10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
10.3.7. Most Popular Publishers: Analysis by Number of Publications
10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.9. Analysis by Popular Keywords
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bioavailability Enhancement: Patent Analysis
11.3.1. Analysis by Application Year
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Bioavailability Enhancement Approach
11.3.4. Analysis by CPC Symbols
11.3.5. Analysis by Geography
11.3.6. Analysis by Emerging Focus Areas
11.3.7. Analysis by Type of Organization
11.3.8. Leading Players: Analysis by Number of Patents
11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations
12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Guidelines To Conduct Bioavailability Studies
12.3. Bioavailability Enhancement: Clinical Trials Analysis
12.3.1. Research Methodology
12.3.2. Analysis of Trials by Trial Registration Year
12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.4. Analysis of Trials by Study Design
12.3.5. Analysis of Trials by Trial Phase
12.3.6. Analysis of Trials by Trial Recruitment Status
12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
12.3.8. Analysis by Type of Molecule and Trial Phase
12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Study Focus
12.3.12. Analysis of Trials by Geography
12.3.13. Analysis of Enrolled Patient Population by Geography
13. TECHNOLOGY EVALUATION FRAMEWORK
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Technologies based on Solid Dispersion Approaches
13.3.1 List of Approved Drugs
13.3.2 Trends in Intellectual Capital
13.3.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.4. Technologies based on Size Reduction Approaches
13.4.1 List of Approved Drugs
13.4.2 Trends in Intellectual Property
13.4.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.5. Technologies based on Lipid-based Approaches
13.5.1 List of Approved Drugs
13.5.2 Trends in Intellectual Property
13.5.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers
13.6. Technology Evaluation Framework: Wind Rose Representation
13.7. Technology Evaluation Framework: Spider Web Representation
13.8. Results and Discussions
14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035
14.4. Analysis by Drug Class, 2022 and 2035
14.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035
14.4.2. Demand for Bioavailability Enhancement Technologies and Services forGenerics, 2022-2035
14.5. Analysis by BCS Classification, 2022 and 2035
14.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS IIDrugs, 2022-2035
14.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCSIV Drugs, 2022-2035
14.6. Analysis by Dosage Form, 2022 and 2035
14.6.1. Demand for Bioavailability Enhancement Technologies and Services forLiquids, 2022-2035
14.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids,2022-2035
14.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035
14.6.4. Demand for Bioavailability Enhancement Technologies and Services for FineParticles / Powders, 2022-2035
14.7. Concluding Remarks
15. MARKET FORECAST AND OPPURTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Global Bioavailability Enhancement Services Market, 2022-2035
15.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, 2022 and 2035
15.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035
15.4.2. Bioavailability Enhancement Services Market for Generics, 2022-2035
15.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, 2022 and 2035
15.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035
15.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035
15.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, 2022 and 2035
15.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches,2022-2035
15.6.2. Bioavailability Enhancement Services Market for Solid DispersionApproaches, 2022-2035
15.6.3. Bioavailability Enhancement Services Market for Size Reduction Approaches,2022-2035
15.6.4. Bioavailability Enhancement Services Market for Other EnhancementApproaches, 2022-2035
15.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form, 2022 and 2035
15.7.1. Bioavailability Enhancement Services Market for Liquids, 2022-2035
15.7.2. Bioavailability Enhancement Services Market for Solids, 2022-2035
15.7.3. Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035
15.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders,2022-2035
15.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, 2022-2035
15.8. Bioavailability Enhancement Services Market: Analysis by Key Geographies, 2022 and 2035
15.8.1. Bioavailability Enhancement Services Market in North America, 2022-2035
15.8.2. Bioavailability Enhancement Services Market in Europe, 2022-2035
15.8.3. Bioavailability Enhancement Services Market in Asia, 2022-2035
15.8.4. Bioavailability Enhancement Services Market in Latin America, 2022-2035
15.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa,2022-2035
15.8.6. Bioavailability Enhancement Services Market in Rest of the World, 2022-2035
15.9. Concluding Remarks
16. CONCLUSION
17. APPENDIX I: LIST OF COMPANIES
18. APPENDIX II: TABULATED DATA
Figure 2.1 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Clinical Trial Analysis
Figure 2.7 Executive Summary: Demand Analysis
Figure 2.8 Executive Summary: Market Forecast
Figure 3.1 Bioavailability Enhancement Technologies: Historical Evolution of Bioavailability Enhancement Technologies
Figure 3.2 Single Dose Study: Drug Concentration-Time Curve
Figure 3.3 Multiple Dose Study: Drug Concentration-Time Curve
Figure 3.4 Different Bioavailability Assessment Methods
Figure 3.5 Biopharmaceutical Classification System
Figure 3.6 Factors Affecting Drug Bioavailability
Figure 3.7 Solid Dispersion Formulations: Classification
Figure 3.8 Solid Dispersion Formulations: Preparation Methodologies
Figure 3.9 Solid Dispersion Formulations: Melt Agglomeration Technique
Figure 3.10 Nanosuspension Formulations: Preparation Methodologies
Figure 3.11 Lipid-based Formulations: Classification
Figure 3.12 Biological Formulations: Classification
Figure 4.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Figure 4.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Figure 4.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Figure 4.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Figure 4.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Figure 4.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 5.1 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Figure 5.2 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Figure 5.3 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 5.6 Leading Players: Distribution by Number of Technologies
Figure 5.7 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Figure 5.8 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Figure 5.9 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 5.10 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Figure 5.11 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Figure 5.12 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Figure 5.13 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Figure 5.14 Bioavailability Enhancement Technologies: Distribution by Availability for License
Figure 5.15 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Figure 6.1 Key Insights: Distribution by Company Size and Location of Headquarters
Figure 6.2 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Figure 6.3 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Figure 6.4 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Figure 6.5 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 6.6 Key Insights: Distribution by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region
Figure 7.1 Catalent: Annual Revenues, 2017-2022 (USD Billion)
Figure 7.2 Lonza: Annual Revenues, 2017-2022 H1 (CHF Billion)
Figure 7.3 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, 2017-2022 H1 (USD Billion)
Figure 8.1 Company Benchmarking Analysis: Distribution by Year of Establishment and Location of Headquarters
Figure 8.2 Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
Figure 8.3 Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
Figure 8.4 Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
Figure 8.5 Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
Figure 8.6 Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
Figure 8.7 Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
Figure 8.8 Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
Figure 8.9 Benchmarking of Players based in Asia and Rest of the World, Established Post-2000 (Peer Group VIII)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Figure 9.8 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Partner Headquarters
Figure 10.1 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Figure 10.4 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Figure 10.5 Most Popular Journals: Distribution by Number of Publications
Figure 10.6 Most Popular Journals: Distribution by Journal Impact Factor
Figure 10.7 Most Popular Publishers: Distribution by Number of Publications
Figure 10.8 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.9 Publication Analysis: Distribution by Popular Keywords
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Figure 11.3 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Figure 11.4 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents, Pre-2010 - 2022
Figure 11.5 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Figure 11.6 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Figure 11.7 Patent Analysis: Distribution by CPC Symbols
Figure 11.8 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 11.9 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 11.10 Patent Analysis: Distribution by Emerging Focus Area
Figure 11.11 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Figure 11.12 Leading Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.14 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.15 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 11.16 Patent Analysis: Distribution of Patents by Age (Pre-2010 - 2022)
Figure 11.17 Bioavailability Enhancement: Patent Valuation
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2022
Figure 12.3 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.4 Bioavailability Studies: Distribution of Trials by Study Design
Figure 12.5 Bioavailability Studies: Distribution of Trials by Trial Phase
Figure 12.6 Bioavailability Studies: Distribution of Trials by Recruitment Status
Figure 12.7 Bioavailability Studies: Distribution of Trials by Type of Sponsor / Collaborator
Figure 12.8 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Figure 12.9 Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.10 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.11 Bioavailability Studies: Distribution by Study Focus
Figure 12.12 Bioavailability Studies: Geographical Distribution of Trials
Figure 12.13 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Figure 13.1 Technologies based on Lipid-based Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.2 Technologies based on Lipid-based Approaches: Trends in Research Activity (Number of Publications)
Figure 13.3 Technologies Evaluation Framework: Lipid-based Approaches
Figure 13.4 Technologies based on Size Reduction Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.5 Technologies based on Size Reduction Approaches: Trends in Research Activity (Number of Publications)
Figure 13.6 Technologies Evaluation Framework: Size Reduction Approaches
Figure 13.7 Technologies based on Solid Dispersion Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.8 Technologies based on Solid Dispersion Approaches: Trend in Research Activity (Number of Publications)
Figure 13.9 Technologies Evaluation Framework: Solid Dispersion Approaches
Figure 13.10 Technologies based on Other Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.11 Technologies based on Other Approaches: Trends in Research Activity (Number of Publications)
Figure 13.12 Technologies Evaluation Framework: Other Approaches
Figure 13.13 Technology Evaluation Framework: Spider Web Representation
Figure 14.1 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Figure 14.2 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035
Figure 14.3 Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035 (In Terms of Number of Projects)
Figure 14.4 Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035 (In Terms of Number of Projects)
Figure 14.5 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035
Figure 14.6 Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 14.7 Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 14.8 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035
Figure 14.9 Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035 (In Terms of Number of Projects)
Figure 14.10 Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035 (In Terms of Number of Projects)
Figure 14.11 Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035 (In Terms of Number of Projects)
Figure 14.12 Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035 (In Terms of Number of Projects)
Figure 15.1 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Billion)
Figure 15.2 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035
Figure 15.3 Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035 (USD Billion)
Figure 15.4 Bioavailability Enhancement Services Market for Generics, 2022-2035 (USD Billion)
Figure 15.5 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035
Figure 15.6 Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035 (USD Billion)
Figure 15.7 Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035 (USD Billion)
Figure 15.8 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035
Figure 15.9 Bioavailability Enhancement Services Market for Lipid-Based Approaches, 2022-2035 (USD Billion)
Figure 15.10 Bioavailability Enhancement Services Market for Size Reduction Approaches, 2022-2035 (USD Billion)
Figure 15.11 Bioavailability Enhancement Services Market for Solid Dispersion Approaches, 2022-2035 (USD Billion)
Figure 15.12 Bioavailability Enhancement Services Market for Other Approaches, 2022-2035 (USD Billion)
Figure 15.13 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035
Figure 15.14 Bioavailability Enhancement Services Market for Liquids, 2022-2035 (USD Billion)
Figure 15.15 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Billion)
Figure 15.16 Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035 (USD Billion)
Figure 15.17 Bioavailability Enhancement Services Market for Fine Particles / Powders, 2022-2035 (USD Billion)
Figure 15.18 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035
Figure 15.19 Bioavailability Enhancement Services Market in North America, 2022-2035 (USD Billion)
Figure 15.20 Bioavailability Enhancement Services Market in Europe, 2022-2035 (USD Billion)
Figure 15.21 Bioavailability Enhancement Services Market in Asia, 2022-2035 (USD Billion)
Figure 15.22 Bioavailability Enhancement Services Market in Latin America, 2022-2035 (USD Billion)
Figure 15.23 Bioavailability Enhancement Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 15.24 Bioavailability Enhancement Services Market in Rest of the World, 2022-2035 (USD Billion)
Figure 15.25 Bioavailability Enhancement Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Billion)
Figure 16.1 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 16.2 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 16.3 Concluding Remarks: Partnerships and Collaborations
Figure 16.4 Concluding Remarks: Publication Analysis
Figure 16.5 Concluding Remarks: Patent Analysis
Figure 16.6 Concluding Remarks: Clinical Trial Analysis
Figure 16.7 Concluding Remarks: Demand Analysis
Figure 16.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 16.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
Table 4.1 List of Bioavailability Enhancement Service Providers
Table 4.2 Bioavailability Enhancement Service Providers: Information on BioavailabilityEnhancement Principle
Table 4.3 Bioavailability Enhancement Service Providers: Information on BioavailabilityEnhancement Approach
Table 4.4 Bioavailability Enhancement Service Providers: Information on Solid DispersionApproaches
Table 4.5 Bioavailability Enhancement Service Providers: Information on Size ReductionApproaches
Table 4.6 Bioavailability Enhancement Service Providers: Information on Lipid-BasedApproaches
Table 4.7 Bioavailability Enhancement Service Providers: Information on OtherBioavailability Enhancement Approaches
Table 4.8 Bioavailability Enhancement Service Providers: Information on Dosage Forms
Table 4.9 Bioavailability Enhancement Service Providers: Information on Routes ofAdministration
Table 5.1 List of Bioavailability Enhancement Technology Providers
Table 5.2 Bioavailability Enhancement Technologies: Information on BioavailabilityEnhancement Principles and Bioavailability Enhancement Approaches
Table 5.3 Bioavailability Enhancement Technologies: Information on Type of Molecule
Table 5.4 Bioavailability Enhancement Technologies: Information on Dosage Forms
Table 5.5 Bioavailability Enhancement Technologies: Information on Routes ofAdministration
Table 5.6 Bioavailability Enhancement Technologies: Information on Availability forLicense and Intellectual Property Rights
Table 7.1 List of Companies Profiled
Table 7.2 Adare Pharma Solutions: Company Snapshot
Table 7.3 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 7.4 Ascendia Pharmaceuticals: Company Snapshot
Table 7.5 Ascendia Pharmaceuticals: Recent Developments and Future Outlook
Table 7.6 Catalent: Company Snapshot
Table 7.7 Catalent: Recent Developments and Future Outlook
Table 7.8 Lonza: Company Snapshot
Table 7.9 Lonza: Recent Developments and Future Outlook
Table 7.10 Lubrizol Life Science Health: Company Snapshot
Table 7.11 Lubrizol Life Science Health: Recent Developments and Future Outlook
Table 7.12 Pace Life Sciences: Company Snapshot
Table 7.13 Pace Life Sciences: Recent Developments and Future Outlook
Table 7.14 Quotient Sciences: Company Snapshot
Table 7.15 Quotient Sciences: Recent Developments and Future Outlook
Table 7.16 WuXi STA (A Subsidiary of WuXi AppTec): Company Snapshot
Table 7.17 WuXi STA (A Subsidiary of WuXi AppTec): Recent Developments and FutureOutlook
Table 9.1 Bioavailability Enhancement: List of Partnerships and Collaborations, 2013-2022
Table 9.2 Bioavailability Enhancement Focused Partnerships and Collaborations:Information on Type of Agreement (Region-wise and Geography-wise)
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 12.1 Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 13.1 Technologies based on Lipid-based Approaches: List of Approved Drugs
Table 13.2 Technologies Based on Lipid-based Approaches: Global Competition
Table 13.3 Technologies based on Size Reduction Approaches: List of Approved Drugs
Table 13.4 Technologies Based on Size Reduction Approaches: Global Competition
Table 13.5 Technologies based on Solid Dispersion Approaches: List of Approved Drugs
Table 13.6 Technologies Based on Solid Dispersion Approaches: Global Competition
Table 13.7 Technologies based on Other Approaches: List of Approved Drugs
Table 13.8 Technologies Based on Other Approaches: Global Competition
Table 18.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Table 18.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 18.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Table 18.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 18.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Table 18.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Table 18.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 18.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Table 18.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Table 18.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 18.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 18.13 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Table 18.14 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Table 18.15 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Table 18.16 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.17 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Table 18.18 Leading Players: Distribution by Number of Technologies
Table 18.19 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Table 18.20 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Table 18.21 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.22 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Table 18.23 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Table 18.24 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Table 18.25 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Table 18.26 Bioavailability Enhancement Technologies: Distribution by Availability for License
Table 18.27 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Table 18.28 Key Insights: Distribution by Company Size and Location of Headquarters
Table 18.29 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Table 18.30 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Table 18.31 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Table 18.32 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.33 Catalent: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 18.34 Lonza: Annual Revenues, FY 2017-HI FY 2022 (CHF Billion)
Table 18.35 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, FY 2017- H1 FY 2022 (USD Billion)
Table 18.36 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Table 18.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.39 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 18.41 Most Active Players: Distribution by Number of Partnerships
Table 18.42 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Table 18.43 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Table 18.44 Partnerships and Collaboration: Distribution by Type of Partnership and Location of Partner Headquarters
Table 18.45 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Table 18.46 Publication Analysis: Distribution by Type of Publication
Table 18.47 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.48 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Table 18.49 Most Popular Journals: Distribution by Number of Publications
Table 18.50 Most Popular Journals: Distribution by Journal Impact Factor
Table 18.51 Most Popular Publishers: Distribution by Number of Publications
Table 18.52 Most Popular Copyright Holders: Distribution by Number of Publications
Table 18.53 Patent Analysis: Distribution by Type of Patent
Table 18.54 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Table 18.55 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Table 18.56 Patent Analysis: Distribution by Year-wise Trend of Filed Patent Applications and Number of Granted Patents, Pre-2010-2022
Table 18.57 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.58 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Table 18.59 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 18.60 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 18.61 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Table 18.62 Leading Industry Players: Distribution by Number of Patents
Table 18.63 Leading Non-Industry Players: Distribution by Number of Patents
Table 18.64 Leading Patent Assignees: Distribution by Number of Patents
Table 18.65 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Table 18.66 Patent Analysis: Distribution of Patents by Age (pre-2010-2022)
Table 18.67 Bioavailability Enhancement: Patent Valuation
Table 18.68 Leading Patents: Distribution by Number of Citations
Table 18.69 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 18.70 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 18.71 Bioavailability Studies: Distribution of Trials by Study Design
Table 18.72 Bioavailability Studies: Distribution of Trials by Trial Phase
Table 18.73 Bioavailability Studies: Distribution of Trials by Recruitment Status
Table 18.74 Bioavailability Studies: Distribution of Trials by Type of Sponsor /Collaborator
Table 18.75 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Table 18.76 Leading Industry Players: Distribution by Number of Registered Trials
Table 18.77 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 18.78 Bioavailability Studies: Geographical Distribution of Trials
Table 18.79 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Table 18.80 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Table 18.81 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035 (In Terms of Number of Projects)
Table 18.82 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035 (In Terms of Number of Projects)
Table 18.83 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035 (In Terms of Number of Projects)
Table 18.84 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Million)
Table 18.85 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035 (USD Million)
Table 18.86 Bioavailability Enhancement Services Market for New Drug Approvals, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.87 Bioavailability Enhancement Services Market for Generics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.88 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035 (USD Million)
Table 18.89 Bioavailability Enhancement Services Market for BCS II Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.90 Bioavailability Enhancement Services Market for BCS IV Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.91 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035 (USD Million)
Table 18.92 Bioavailability Enhancement Services Market for Lipid Based Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.93 Bioavailability Enhancement Services Market for Solid Dispersion Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.94 Bioavailability Enhancement Services Market for Size Reduction Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.95 Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.96 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035 (USD Million)
Table 18.97 Bioavailability Enhancement Services Market for Liquids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.98 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Million)
Table 18.99 Bioavailability Enhancement Services Market for Semi-Solids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.100 Bioavailability Enhancement Services Market for Fine Particles / Powders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.101 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035 (USD Million)
Table 18.102 Bioavailability Enhancement Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.103 Bioavailability Enhancement Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.104 Bioavailability Enhancement Services Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.105 Bioavailability Enhancement Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.106 Bioavailability Enhancement Services Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.107 Bioavailability Enhancement Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
The following companies and organizations have been mentioned in the report: